Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9961170 | 0.93 | CTSK (0.43) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL9961219 | 0.91 | CYP2D6 (0.44) | CTSKCYP2D6 | |
| SCHEMBL9961228 | 0.88 | CTSK (0.41) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL7884932 | 0.82 | CYP2D6 (0.45) | CTSKCYP2D6 | |
| SCHEMBL7887187 | 0.81 | CTSK (0.41) | CTSKCYP2D6 | |
| SCHEMBL9961171 | 0.80 | CYP1A2 (0.44) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL7959731 | 0.78 | CTSK (0.41) | CTSKCYP2D6 | |
| SCHEMBL21550268 | 0.78 | CYP1A2 (0.49) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL19944871 | 0.78 | CYP2D6 (0.43) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL13471107 | 0.78 | CYP2D6 (0.43) | CTSKCYP1A2CYP2C9CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, VIP, CASP5 | CTSK 90/4885CYP1A2 2114/4885CYP2C9 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.